UPDATE 1-J&J says its psoriasis drug superior to Novartis' in study

Johnson & Johnson said its drug Tremfya was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.